Compare ALEMBIC PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PFIZER ALEMBIC PHARMA/
PFIZER
 
P/E (TTM) x 24.3 40.3 60.2% View Chart
P/BV x 7.2 6.8 105.5% View Chart
Dividend Yield % 0.5 0.5 105.8%  

Financials

 ALEMBIC PHARMA   PFIZER
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PFIZER
Mar-19
ALEMBIC PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6643,840 17.3%   
Low Rs4122,080 19.8%   
Sales per share (Unadj.) Rs208.7455.0 45.9%  
Earnings per share (Unadj.) Rs31.093.8 33.1%  
Cash flow per share (Unadj.) Rs37.1109.4 33.9%  
Dividends per share (Unadj.) Rs5.5022.50 24.4%  
Dividend yield (eoy) %1.00.8 134.4%  
Book value per share (Unadj.) Rs144.2658.2 21.9%  
Shares outstanding (eoy) m188.5245.75 412.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.66.5 39.6%   
Avg P/E ratio x17.431.6 55.0%  
P/CF ratio (eoy) x14.527.1 53.6%  
Price / Book Value ratio x3.74.5 83.0%  
Dividend payout %17.724.0 74.0%   
Avg Mkt Cap Rs m101,461135,420 74.9%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m7,4673,238 230.6%   
Avg. sales/employee Rs ThNM7,911.4-  
Avg. wages/employee Rs ThNM1,230.9-  
Avg. net profit/employee Rs ThNM1,630.7-  
INCOME DATA
Net Sales Rs m39,34720,815 189.0%  
Other income Rs m941,674 5.6%   
Total revenues Rs m39,44122,489 175.4%   
Gross profit Rs m8,7365,712 152.9%  
Depreciation Rs m1,152714 161.4%   
Interest Rs m18473 252.5%   
Profit before tax Rs m7,4936,599 113.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5682,309 67.9%   
Profit after tax Rs m5,8444,291 136.2%  
Gross profit margin %22.227.4 80.9%  
Effective tax rate %20.935.0 59.8%   
Net profit margin %14.920.6 72.1%  
BALANCE SHEET DATA
Current assets Rs m19,57727,167 72.1%   
Current liabilities Rs m14,8968,917 167.1%   
Net working cap to sales %11.987.7 13.6%  
Current ratio x1.33.0 43.1%  
Inventory Days Days9068 132.3%  
Debtors Days Days4530 150.7%  
Net fixed assets Rs m27,0978,862 305.8%   
Share capital Rs m377458 82.4%   
"Free" reserves Rs m26,81129,656 90.4%   
Net worth Rs m27,18830,113 90.3%   
Long term debt Rs m4,99325 19,972.0%   
Total assets Rs m47,77839,400 121.3%  
Interest coverage x41.791.5 45.6%   
Debt to equity ratio x0.20 22,120.8%  
Sales to assets ratio x0.80.5 155.9%   
Return on assets %12.611.1 113.9%  
Return on equity %21.514.2 150.9%  
Return on capital %23.622.1 106.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,453428 4,541.8%   
Fx outflow Rs m6,065786 771.2%   
Net fx Rs m13,388-358 -3,738.6%   
CASH FLOW
From Operations Rs m8,120978 830.1%  
From Investments Rs m-7,556351 -2,151.5%  
From Financial Activity Rs m590-1,099 -53.7%  
Net Cashflow Rs m1,153231 499.7%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 4.9 185.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.7 58.6%  
Shareholders   49,328 85,207 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 433 Points; Banking and Auto Stocks Bleed(Closing)

Indian share markets ended on a negative note today amid a huge selloff in auto and banking stocks.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

3 Stocks to Ride the Big Rebound in Smallcaps(Profit Hunter)

Aug 11, 2020

The rebound ratio suggests that smallcaps are set for big gains but this time it will be limited to a few stocks. Make sure you choose wisely.

Governance: For the Country and Your Portfolio(The Honest Truth)

Aug 14, 2020

Ajit Dayal on the need of socially responsible governance.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2020 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - FULFORD INDIA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS